Skip to main content

CURE

ETF

CURE

ETF
—
—

Performance overview

CURE Price
Price Chart

Forward-looking statistics

Beta
2.07
Risk
35.49%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.

Fund info

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.

Investing methodPassively Managed
DiversifiedNo
Expense ratio1.12%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$1.38
Revenue per share—
Avg trading volume (30 day)$6M
Avg trading volume (10 day)$5M
Put-call ratioN/A

Macro factor sensitivity

Growth+2.4
Credit+5.5
Liquidity-0.5
Inflation-4.8
Commodities+0.4
Interest Rates-2.5

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayMarch 25, 2025

News

5 Leveraged ETFs With Double-Digit Gains Halfway Through Q1

We highlight a bunch of the best-performing leveraged equity ETFs halfway through the first quarter.

Zacks Investment Research (February 24, 2025)
Amid Monkeypox Outbreak, This 3X Leveraged ETF Provides Exposure To Health Sector: What To Watch

The Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) gapped up almost 2.52% higher on Monday in response to outbreaks of monkeypox being reported in several western nations. CURE is a triple leveraged fund that is designed to outperform 72 U.S. companies in the home health care sector.

Benzinga (May 23, 2022)
Jablonski: Biotech presents a good buying opportunity

Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.

CNBC Television (November 12, 2019)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free